# US 2022/0034780 A1 · Multiplexed on-chip impedance cytometry system and method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0034780 A1
- Document ID: US20220034780A1
- Status: Published application
- Kind: A1
- Application number: 17/280,480
- Filed: 2019-09-26
- Published: 2022-02-03
- Earliest claimed: 2018-09-26
- Assignees: University of Virginia Patent Foundation
- Applicants: University of Virginia Patent Foundation
- Inventors: Nathan SWAMI; John MCGRATH; Walter VARHUE; Carlos HONRADO; Vahid FARMEHINI; Yi LIU
- Web page: https://patentgrep.com/patent/US20220034780A1

## CPC

- G01N 15/1023: {Microstructural devices for non-optical measurement}
- B01L 3/502761: {specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads or physically stretching molecules}
- B03C 5/005: {Dielectrophoresis, i.e. dielectric particles migrating towards the region of highest field strength}
- B03C 5/026: {using open-gradient differential dielectric separation, i.e. using electrodes of special shapes for non-uniform field creation, e.g. Fluid Integrated Circuit [FIC]}
- G01N 15/1031: by measuring electrical or magnetic effects
- B01L 2200/027: for microfluidic devices
- B01L 2200/0652: Sorting or classification of particles or molecules
- B01L 2200/10: Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
- B01L 2300/0645: Electrodes
- B01L 2400/0424: Dielectrophoretic forces
- B01L 2400/086: using baffles or other fixed flow obstructions
- B03C 2201/24: for measuring or calculating of parameters, e.g. efficiency
- B03C 2201/26: for use in medical or biological applications
- B03C 2201/32: Checking the quality of the result or the well-functioning of the device
- G01N 2015/1006: {for cytology}
- G01N 2015/1028: {Sorting particles}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B03C: MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS (separating isotopes B01D59/00; combinations of magnetic or electrostatic separation with separation of solids by other means B03B, B07B)

## Abstract

An exemplary method and system is disclosed that facilitate the integration of multiplexed single-cell impedance cytometry in a high throughput format, which can be deployed upstream from microfluidic sample preparation and/or downstream to microfluidic cell separation. In exemplary method and system may employ impedance-based quantification of cell electrophysiology on the same microfluidic chip (i.e., “on-chip”) to provide distinguishing phenotypic information on the sample, without the need for additional sample handling, preparation or dilution steps as would be needed for other flow cytometry techniques.

## Claims

### Claim 1

A method of operating a microfluidic chip, the method comprising:
flowing a sample comprising biologic or particle components in a plurality of microfluidic channels of the microfluidic chip, including an upstream microfluidic channel and a plurality of downstream microfluidic channels, wherein the upstream microfluidic channel is connected to the plurality of downstream microfluidic channels;
applying a first set of electric field across a first set of one or more electrodes located in the upstream microfluidic channel to selectively urge the biologic or particle components into one or more lanes of a plurality of lanes in a flow to continuously separate the biologic or particle components to channel inlets of the plurality of downstream microfluidic channels;
applying a second set of electric field across a second set of one or more electrodes located in at least one downstream microfluidic channel of the plurality of downstream microfluidic channels, including in a first downstream microfluidic channel; and
interrogating, via the second set of one or more electrodes, electrical responses of the separated biologic or particle components in the at least one downstream microfluidic channel, including electrical responses of the separated biologic or particle components in the first downstream microfluidic channel,
wherein the electrical responses are analyzed via impedance magnitude-based contrast and/or impedance phase-based contrast for quantification and/or analysis of the separated biologic or particle components in at least the first downstream microfluidic channel.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
quantifying impedance magnitude and/or impedance phase characteristics of the separated biologic or particle components sorted into the second downstream microfluidic channel using the second set of one or more electrodes located in the first downstream microfluidic channel; and
quantifying impedance and/or phase impedance characteristics of separated biologic or particle components sorted into a second downstream microfluidic channel using a third set of one or more electrodes located in the second microfluidic channel.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the electrical responses of the separated biologic or particle components in the first and second downstream microfluidic channels are measured simultaneously, and wherein the acquired electrical responses are converted to a digitally encoded signal via a common amplifier circuit.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein signals associated with the interrogated electrical responses of the separated biologic or particle components in the first and second downstream microfluidic channels are frequency-division multiplexed into a common bus, and wherein the common bus is connected to the common amplifier circuit.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the first and second sets of the one or more electrodes are connected to a respective signal source, where each of the respective signal source has a distinct frequency to that of the others to facilitate frequency-division multiplexing.

### Claim 6 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the second set of the one or more electrodes has a first set of spacings among individual electrodes of the set, and wherein the third set of one or more electrodes has a second set of spacings among individual electrodes of the set, wherein the first set of spacings is different from the second set of spacings, and
wherein a single source signal when applied to the different spacings of the first set of spacings and the second set of spacings results in the second set of electrodes generating a field having a different temporal profile of impedance in comparison to that of the third set of electrodes.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, further comprising:
detecting, via one or more position detection electrodes located in the first downstream microfluidic channel, presence of the separated biologic or particle components in the first microfluid channel, wherein the detected presence of the separated biologic or particle components in the first microfluid channel is used for selective interrogation, selective sampling, and/or selective multiplexing of the separated biologic or particle components in the first microfluid channel.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the interrogated electrical responses are measured in the first downstream microfluidic channel while the separated biologic or particle components is continuously flowing in the first downstream microfluidic channel.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the interrogated electrical responses are measured in the first downstream microfluidic channel while the separated biologic or particle components are at a gated position in the first downstream microfluidic channel.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the second set of electric field applied across the second set of one or more electrodes is similarly, or same, across multiple measurements of the multiple biologic or particle components flowing through the first downstream microfluidic channel.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein a same set of different frequencies are applied, across multiple measurements, to each group of multiplexed downstream microfluidic channels.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the second set of electric field applied across the second set of one or more electrodes is varied across multiple measurements of the multiple biologic or particle components flowing through the first downstream microfluidic channel.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 12)

The method of any one of claims 1-9 and 12, wherein different frequencies are swept, across multiple measurements, across each respective group of multiplexed downstream microfluidic channels.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein levels of impedance or value associated therewith is determined by analog circuit configured to:
detect small time shifts in incoming signals in a differential manner via a PLL phase extractor circuit to enable noise rejection for extracting a phase signal of the measured signal associated with current flow;
averaging the phase signal; and
converting the averaged phase signal to a binary stream of the averaged phase signal. Amplitude: customizing comparator-based peak detection for accurate amplitude measurement over wide input dynamic range and wide frequency band by tuning the charging current inside the peak detector to be invariant on the voltage of the charge-holding capacitor, thereby enabling more sensitive comparisons for peak detection

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the first downstream microfluidic channel has at least one region having a cross-sectional area different to the channel, wherein the cross-sectional area is sized to increase or reduce velocity of the flow through the first downstream microfluidic channel to improve sensitivity and/or signal-to-noise performance of the measurement.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the downstream microfluidic channel includes a third microfluidic channel that splits into a plurality of parallel channels, wherein each of the plurality of parallel channels defines a second flow rate different than the flow rate of the channel feeding the plurality of parallel channels.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the second set of one or more electrodes located in the first downstream microfluidic channel is composed predominantly of a nanostructured or nanoporous gold, graphene, platinum material.

### Claim 18 (depends on 12)

The method of claim 12, wherein the nanoporous gold has been modified with a self-assembled monolayer for electrode passivation against species in the electrolyte sample and/or for selectivity towards particular species in the electrolyte sample.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the applied first electric field continuously separates the biologic or particle components into the first downstream microfluidic channel based on the impedance characteristics of the biologic or particle components.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the applied first set of electric field continuously separates the biologic or particle components into the second downstream microfluidic channel, wherein the biologic or particle components sorted to the second downstream microfluidic channel has a different permittivity or conductivity characteristics to the biologic or particle components sorted to the second microfluidic channel.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the first set of electric field includes a first field applied across electrodes in the first upstream microfluidic channel and a second field applied across electrodes in the first upstream microfluidic channel, wherein the first field has a first predominant frequency component and the second field has a second predominant frequency component, and wherein the first predominant frequency component is the same as the second predominant frequency component.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the first set of electric field includes a first field applied across electrodes in the first upstream microfluidic channel and a second field applied across electrodes in the first upstream microfluidic channel, wherein the first electric field and the second electric field have the same frequency component, and wherein the second field is 180-degree phase-shifted with respect to the first field.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the first set of electric field includes a first field applied across electrodes in the first upstream microfluidic channel and a second field applied across electrodes in the first upstream microfluidic channel, and wherein the first field and the second field have a same frequency component, the second electric field being n-degree phase-shifted with respect to the first field.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the separated biologic or particle components comprises cells, and wherein the separation is at a rate greater than 100 cells per second.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1-24 further comprising:
continuously directing the biologic or particle components via an inertial focusing structure or a deterministic lateral displacement structure located within, or defining, the first microfluidic channel.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the impedance magnitude contrast characteristics and/or impedance phase contrast characteristics are used to stratify lineage of cells or to stratify cells with phenotypic heterogeneity based on disease onset and/or drug resistance.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the biologic or particle components comprise sorted cells free of labels.

### Claim 28

A method comprising:
quantifying impedance characteristics of biologic or particle components in a microfluidic channel of a microfluidic chip, wherein the quantification is performed using a set of electrodes located in the microfluidic channel by:
sweeping a frequency varying electric field to the set of electrodes over a frequency range starting at a first frequency to a second frequency;
measuring resulting varying electrical signal from the application of the frequency varying electric field to the biologic or particle components; and
determining phase and amplitude signal, or value associated therewith, of a measured signal associated with current flow; and
wherein the determined phase and amplitude signal is used to stratify lineage of cells or to stratify cells with phenotypic heterogeneity based on disease onset and/or drug resistance.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A fluidic chip apparatus comprising:
a plurality of microfluidic channels configured to receive a sample comprising biologic or particle components, wherein the plurality of microfluidic channels includes a first microfluidic channel, a second microfluidic channel, and a third microfluidic channel, and wherein the first microfluidic channel is connected to the second microfluidic channel and the third microfluidic channel; and
one or more sets of electrodes located in the first microfluidic channel, wherein the one or more sets of electrodes are configured to continuously separates the biologic or particle components into the second microfluidic channel based on impedance characteristics of the biologic or particle components, wherein the separated biologic or particle components are subsequently quantified and/or analyzed via an impedance-based quantification of cell electrophysiology in accordance with the steps of method claims 1-25.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A fluidic chip apparatus comprising:
a plurality of microfluidic channels configured to receive a sample comprising biologic or particle components, wherein the plurality of microfluidic channels includes a first microfluidic channel, a second microfluidic channel, and a third microfluidic channel, and wherein the first microfluidic channel is connected to the second microfluidic channel and the third microfluidic channel; and
one or more sets of electrodes located in the second microfluidic channel, wherein the one or more sets of electrodes are configured to apply frequency varying electric field to the biologic or particle components, and wherein the resulting varying electrical signal comprises a quantified impedance characteristics associated with electrophysiology of the biologic or particle components, wherein determined phase and amplitude data set of the quantified impedance characteristics is used to stratify lineage of cells or to stratify cells with phenotypic heterogeneity based on disease onset and/or drug resistance in accordance with the steps of method claims 1-25.

### Claim 31 (depends on 29, 30)

A cytometry system comprising the fluidic chip of claim 29 or 30.

### Claim 32

An impedance phase cytometry method, comprising:
that quantifying, via impedance phase contrast performed by on-chip analysis, positions of multi-cell samples aggregated into a microfluidic channel; and
selectively triggering downstream separation downstream to the positions based on the quantification.
